

## **BrainCool AB (publ) - order of BrainCool System in Germany**

BrainCool has received an order from the University Hospital in Erlangen, for the product BrainCool System. The order of one system is from the department of neurology for the hypothermia treatment of stroke patients. Delivery is scheduled for the end of March 2020.

CEO Martin Waleij comments

The order is important for two reasons, partly because Erlangen is one of the leading clinics in Germany and partly that the product will be used to treat stroke patients.

We also see the order as a confirmation that the market for intensive care medical technology is prioritized even during the turbulence with Covid 19. Although it is more difficult to book meetings with hospitals in our direct sales markets USA and Germany, our evaluations and processes are prioritized by the intensive care units of hospitals.

*This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on March 19, 2020.*

### **For more information**

Martin Waleij – CEO

+46 - 733 -93 70 76

E-mail: [martin.waleij@braincool.se](mailto:martin.waleij@braincool.se)

### **About BrainCool AB (publ)**

*BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.*